APPARATUS FOR PLASMATIZING SOLID-FUEL COMBUSTION ADDITIVE AND METHOD FOR USING THE SAME

An apparatus for plasmatizing solid-fuel combustion additive and the method for using the same are provided. The apparatus is made from a reaction vessel, electrodes, a power supply, a carrier gas intake device, a feed device and an outlet of the plasmatization reaction vessel. The method to use this apparatus is as following: The additive is added into the reaction vessel through the feed device in which the carrier gas passes and carries the additive into the electrode region for evaporation and (partially) plasmatization; and the plasmatized gas from the outlet of the reactor is introduced into any combustion chamber. The additive is an organometallic compound or a mixture of the organometallic compounds, or their derivative, eutectic compound or coordination agent containing at least one organometallic compound. The present invention provides a method for plasmatizing combustion additive, then the plasmatized combustion additive is added into the combustion system to participate the combustion reaction between fuel and oxygen, in turn, to improve the utilization efficiency of the additive, reduce the amount of the additive used, improve the combustion efficiency and quality of the flue gas, then to save the fuel and reduce the emission of the gaseous contaminates. 1. An apparatus for plasmatizing a solid-fuel combustion additive , which comprises:a reaction vessel, mainly for providing the space for plasma reaction and for supporting the installation of the electrodes, the carrier gas intake device, the additive feed device and the outlet of the reaction vessel;{'sup': 6', '18', '−3, 'electrodes, including a cathode and an anode, fixed inside the reaction vessel or on the inner wall of the vessel. The cathode and anode are respectively connected to the cathode and anode of a high-voltage power supply. The set-up of the electrodes must ensure that all or most of a carrier gas that enters the reaction vessel passes through the space between the electrodes (the ...

Anti-ifnar1 antibodies for treating autoimmune diseases

Provided are antibodies or fragments thereof having binding specificity to the human interferon alpha and beta receptor subunit 1 (IFNAR1) protein. In various examples, the antibodies or fragments thereof include a VH and VL CDRs as provided, or variants thereof. Methods of using the antibodies or fragments thereof for treating autoimmune diseases and disorders are also provided.

Anti-ifnar1 antibodies for treating autoimmune diseases.

Se proporcionan anticuerpos o fragmentos de los mismos que tienen especificidad de unión a la proteína de la subunidad 1 del receptor de interferón alfa y beta humano (IFNAR1). En varios ejemplos, los anticuerpos o fragmentos de los mismos incluyen CDRs VH y VL proporcionadas, o variantes de las mismas. También se proporcionan métodos para utilizar los anticuerpos o fragmentos de los mismos para tratar enfermedades o trastornos autoinmunitarios.

Anti-lair1 antibodies and their uses

Provided are anti-LAIR1 antibodies and uses thereof in the treatment of cancer, inflammation and autoimmune diseases. LAIR1 targeting leukemia blast cells would represent a safer and more effective treatment modality for AML patients. Furthermore, using hybridoma screening technique, anti-human LAIR1 specific monoclonal antibodies are successfully generated, where the antibodies inhibited the binding of LAIR1 to collagen I, and showed strong internalization in a dose-dependent manner, indicating the potentials in the development of antibody-drug conjugate.

Method of evaluating progression of an infectious disease and/or inflammatory disease

There is provided a method of evaluating risk of severe outcome of an infectious disease and/or an inflammatory disease in a patient, the method comprising: determining/measuring the number of one or more immune cells selected from the group consisting of VD2 T cells, CD8 T cells, and immature neutrophils in a sample obtained from the patient, wherein the patient has an enhanced risk of severe infectious disease and/or inflammatory disease outcome when: (i) the ratio of immature neutrophils to VD2 T cell is at least 2:1, and/or (ii) the ratio of immature neutrophils to CD8 T cell is at least 0.5:1. Also disclosed are method of treating a patient with a severe infectious disease and/or inflammatory disease and kit for use in methods thereof.

Anti-IFNAR1 antibodies for treating autoimmune diseases

Provided are antibodies or fragments thereof having binding specificity to the human interferon alpha and beta receptor subunit 1 (IFNAR1) protein. In various examples, the antibodies or fragments thereof include a VH and VL CDRs as provided, or variants thereof. Methods of using the antibodies or fragments thereof for treating autoimmune diseases and disorders are also provided.

Anti-ifnar1 antibodies for treating autoimmune diseases

Provided are antibodies or fragments thereof having binding specificity to the human interferon alpha and beta receptor subunit 1 (IFNAR1) protein. In various examples, the antibodies or fragments thereof include a VH and VL CDRs as provided, or variants thereof. Methods of using the antibodies or fragments thereof for treating autoimmune diseases and disorders are also provided.

Grouped hatching incubator tray apparatus for quails for test

Anti-ifnar1 antibodies for treating autoimmune disease

Provided are antibodies or fragments thereof having binding specificity to the human interferon alpha and beta receptor subunit 1 (IFNAR1) protein. In various examples, the antibodies or fragments thereof include a VH and VL CDRs as disclosed herein, or variants thereof. Methods of using the antibodies or fragments thereof for treating autoimmune diseases and disorders are also provided.

Apparatus for simulating outdoor pond ecosystem

The disclosure provides an apparatus for simulating an outdoor pond ecosystem comprising a plurality of simulated ponds connected together by pipelines and the plurality of simulated ponds comprise an adjusting pool, a plurality of control groups, and a plurality of treatment groups with different concentrations; the plurality of control groups and the treatment groups with different concentrations are randomly distributed in the ponds according to a random draw method or a random allocation method, and the adjusting pool is a transfer station for water inlets and outlets of the ponds. According to the apparatus for simulating the outdoor pond ecosystem, the plurality of control groups and treatment groups with different concentrations are arranged in a system, achieving a scale of a middle-scale pond ecological simulation system, which can stimulate an actual complex hydrostatic ecological system including a plurality of aquatic macrophytes, algae, zooplankton, benthos and microorganisms, and evaluate the effects of the complex ecological efficiency caused by chemical pollutants entering an actual water body.

Method of evaluating progression of an infectious disease and/or inflammatory disease

There is provided a method of evaluating risk of severe outcome of an infectious disease and/or an inflammatory disease in a patient, the method comprising: determining/measuring the number of one or more immune cells selected from the group consisting of VD2 T cells, CD8 T cells, and immature neutrophils in a sample obtained from the patient, wherein the patient has an enhanced risk of severe infectious disease and/or inflammatory disease outcome when: (i) the ratio of immature neutrophils to VD2 T cell is at least 2:1, and/or (ii) the ratio of immature neutrophils to CD8 T cell is at least 0.5:1. Also disclosed are method of treating a patient with a severe infectious disease and/or inflammatory disease and kit for use in methods thereof.